Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Invested Capital (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Invested Capital for 13 consecutive years, with $50.9 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 37.23% to $50.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.9 million through Dec 2025, down 37.23% year-over-year, with the annual reading at $70.4 million for FY2025, 38.41% down from the prior year.
  • Invested Capital hit $50.9 million in Q4 2025 for Vistagen Therapeutics, down from $66.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $123.3 million in Q4 2023 to a low of $6.8 million in Q2 2023.
  • Historically, Invested Capital has averaged $65.7 million across 5 years, with a median of $68.4 million in 2025.
  • Biggest five-year swings in Invested Capital: skyrocketed 1810.19% in 2021 and later crashed 85.13% in 2023.
  • Year by year, Invested Capital stood at $80.0 million in 2021, then tumbled by 74.15% to $20.7 million in 2022, then surged by 496.31% to $123.3 million in 2023, then crashed by 34.2% to $81.1 million in 2024, then crashed by 37.23% to $50.9 million in 2025.
  • Business Quant data shows Invested Capital for VTGN at $50.9 million in Q4 2025, $66.3 million in Q3 2025, and $56.8 million in Q2 2025.